Lanifibranor
Metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis
Key Facts
About Hepalys
A Japanese biopharma company developing lanifibranor, a pan-PPAR agonist for MASH, to address liver disease gaps in Asian patients.
View full company profileAbout Hepalys
A Japanese biopharma company developing lanifibranor, a pan-PPAR agonist for MASH, to address liver disease gaps in Asian patients.
View full company profileAbout Inventiva
Inventiva's mission is to develop innovative, oral small molecule therapies for significant unmet medical needs in fibrotic, lysosomal, and oncologic diseases. Its key achievement is the advancement of lanifibranor, a novel pan-PPAR agonist, into a pivotal Phase III trial for MASH/NASH, supported by strong Phase IIb data and regulatory recognition. The company's strategy is built on its proprietary drug discovery platform, strategic partnerships for development and commercialization, and a focus on oral administration to maximize patient compliance and commercial potential.
View full company profileAbout Inventiva
Inventiva's mission is to develop innovative, oral small molecule therapies for significant unmet medical needs in fibrotic, lysosomal, and oncologic diseases. Its key achievement is the advancement of lanifibranor, a novel pan-PPAR agonist, into a pivotal Phase III trial for MASH/NASH, supported by strong Phase IIb data and regulatory recognition. The company's strategy is built on its proprietary drug discovery platform, strategic partnerships for development and commercialization, and a focus on oral administration to maximize patient compliance and commercial potential.
View full company profile